Dominant-negative activity of an α1B-adrenergic receptor signal-inactivating point mutation

被引:35
作者
Chen, SH
Lin, F
Xu, M
Hwa, J
Graham, RM [1 ]
机构
[1] St Vincents Hosp, Mol Cardiol Unit, Victor Chang Cardiac Res Inst, Sydney, NSW 2010, Australia
[2] Univ New S Wales, Sch Biochem & Mol Genet, Kensington, NSW 2033, Australia
[3] MIT, Dept Biol, Cambridge, MA 02139 USA
[4] MIT, Dept Chem, Cambridge, MA 02139 USA
关键词
constitutive activity; G-protein-coupled receptor; inositol phosphate signalling;
D O I
10.1093/emboj/19.16.4265
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
alpha(1)-adrenergic receptors (alpha(1)-ARs) are members of the G-protein-coupled receptor (GPCR) superfamily and activate inositol phosphate (IP) turnover. We show that glycine and asparagine mutations of Phe303 in transmembrane segment VI (TMVI) of the alpha(1B)-AR, a highly conserved residue in GPCRs, although increasing agonist affinity, abolish agonist-activated IF signalling. Co-expression of the Phe303 mutants also inhibited (-)epinephrine-stimulated IP signalling by wild-type alpha(1B)-AR and other G(q)-coupled receptors, as well as IP signalling mediated by AlF4- stimulation of both wild-type G(q alpha) and a constitutively active mutant. The inability of the Phe303 mutants to signal is due to induction of a receptor conformation that dissociates G-protein binding from activation. As a result, the Phe303 mutants sequester G(q alpha) and stoichiometrically inhibit Gq signalling in a dominant-negative manner. We further show that both the enhanced basal and agonist-stimulated IF-signalling activity of the constitutively active alpha(1B)-AR mutants, C128F and A293E, are inhibited in the double mutants, C128F/F303G and A293E/F303G, Phe303, therefore, appears to be critically involved in coupling TMVI alpha-helical movement, a key step in receptor activation, to activation of the cognate G-protein.
引用
收藏
页码:4265 / 4271
页数:7
相关论文
共 25 条
[11]   Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin [J].
Farrens, DL ;
Altenbach, C ;
Yang, K ;
Hubbell, WL ;
Khorana, HG .
SCIENCE, 1996, 274 (5288) :768-770
[12]   RHODOPSIN MUTANTS THAT BIND BUT FAIL TO ACTIVATE TRANSDUCIN [J].
FRANKE, RR ;
KONIG, B ;
SAKMAR, TP ;
KHORANA, HG ;
HOFMANN, KP .
SCIENCE, 1990, 250 (4977) :123-125
[13]   Agonists induce conformational changes in transmembrane domains III and VI of the beta(2) adrenoceptor [J].
Gether, U ;
Lin, S ;
Ghanouni, P ;
Ballesteros, JA ;
Weinstein, H ;
Kobilka, BK .
EMBO JOURNAL, 1997, 16 (22) :6737-6747
[14]   alpha(1)-Adrenergic receptor subtypes - Molecular structure, function, and signaling [J].
Graham, RM ;
Perez, DM ;
Hwa, J ;
Piascik, MT .
CIRCULATION RESEARCH, 1996, 78 (05) :737-749
[15]   Inhibition of gonadotropin-releasing hormone receptor signaling by expression of a splice variant of the human receptor [J].
Grosse, R ;
Schoneberg, T ;
Schultz, G ;
Gudermann, T .
MOLECULAR ENDOCRINOLOGY, 1997, 11 (09) :1305-1318
[16]   Functional interaction of transmembrane helices 3 and 6 in rhodopsin - Replacement of phenylalanine 261 by alanine causes reversion of phenotype of a glycine 121 replacement mutant [J].
Han, M ;
Lin, SW ;
Minkova, M ;
Smith, SO ;
Sakmar, TP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (50) :32337-32342
[17]   A cluster of aromatic residues in the sixth membrane-spanning segment of the dopamine D2 receptor is accessible in the binding-site crevice [J].
Javitch, JA ;
Ballesteros, JA ;
Weinstein, H ;
Chen, JY .
BIOCHEMISTRY, 1998, 37 (04) :998-1006
[18]   A DOMINANT NEGATIVE MUTATION SUPPRESSES THE FUNCTION OF NORMAL EPIDERMAL GROWTH-FACTOR RECEPTORS BY HETERODIMERIZATION [J].
KASHLES, O ;
YARDEN, Y ;
FISCHER, R ;
ULLRICH, A ;
SCHLESSINGER, J .
MOLECULAR AND CELLULAR BIOLOGY, 1991, 11 (03) :1454-1463
[19]   Mutation of Pro-258 in transmembrane domain 6 constitutively activates the G protein-coupled alpha-factor receptor [J].
Konopka, JB ;
Margarit, SM ;
Dube, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (13) :6764-6769
[20]   The role of the aspartate-arginine-tyrosine triad in the m1 muscarinic receptor: Mutations of aspartate 122 and tyrosine 124 decrease receptor expression but do not abolish signaling [J].
Lu, ZL ;
Curtis, CA ;
Jones, PG ;
Pavia, J ;
Hulme, EC .
MOLECULAR PHARMACOLOGY, 1997, 51 (02) :234-241